Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1 Interventional Accepts healthy volunteers

MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)

ClinicalTrials.gov ID: NCT07880379

Public ClinicalTrials.gov record NCT07880379. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a single-center, open-label clinical study designed to evaluate alpha-synuclein (ASYN) deposition in the brain of participants with Parkinson's disease (PD), as compared with healthy elderly (HE) participants. Up to 18 participants (12 PD, 6 HE) are planned to be enrolled. Each participant will receive a single IV injection of \[¹⁸F\]MK-0947 as part of Part 1A followed by PET imaging using the Investigational United Imaging NeuroEXPLORER(NX) camera or the Siemens Biograph mCT camera. If enrolled in Part 1B a second injections and PET scan may be conducted in participants with PD and HE from Part 1A.

Study identification

NCT ID
NCT07880379
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
XingImaging, LLC
Industry
Enrollment
18 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 25, 2026 (Actual)
Primary completion
Sep 30, 2027 (Estimated)
Completion
Sep 30, 2027 (Estimated)
Last update posted
Oct 19, 2026

2026 – 2027

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
XingImaging, LLC New Haven Connecticut 06510 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07880379, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 19, 2026 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07880379 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →